U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Development Resources
  5. Imipenem-cilastatin-relebactam Injection
  1. Development Resources

Imipenem-cilastatin-relebactam Injection

FDA Identified Breakpoints

 

Minimum Inhibitory
Concentrations
(mcg/mL)

Disk Diffusion a
(zone diameter in mm)

Pathogen

S

I

R

S

I

R

Enterobacteriaceae b

M-100 standard is recognized

Pseudomonas aeruginosa

M-100 standard is recognized

Acinetobacter calcoaceticus-baumannii complex

≤2/4

4/4

≥8/4

-

-

-

Haemophilus influenzae

≤4/4

-

-

-

-

-

Anaerobes c,d

M-100 standard is recognized

-

-

-

S = Susceptible; I = Intermediate; R = Resistant

a For disk diffusion, use paper disks impregnated with imipenem/relebactam at a concentration of 10/25 mcg.
b Clinical efficacy was shown for Klebsiella aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Klebsiella oxytoca.
c Clinical efficacy was shown for Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Fusobacterium nucleatum, Parabacteroides distasonis.
d Agar dilution method.

Back to Top